Charles G Drake

Charles G Drake

UNVERIFIED PROFILE

Are you Charles G Drake?   Register this Author

Register author
Charles G Drake

Charles G Drake

Publications by authors named "Charles G Drake"

Are you Charles G Drake?   Register this Author

100Publications

4267Reads

35Profile Views

A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer.

Prostate Cancer Prostatic Dis 2019 Oct 14. Epub 2019 Oct 14.

Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-019-0176-8DOI Listing
October 2019

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.

J Immunother Cancer 2019 Oct 25;7(1):277. Epub 2019 Oct 25.

Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0758-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814994PMC
October 2019

Immunotherapy for Prostate Cancer.

Cold Spring Harb Perspect Med 2019 May 1;9(5). Epub 2019 May 1.

Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York 10032.

View Article

Download full-text PDF

Source
http://perspectivesinmedicine.cshlp.org/lookup/doi/10.1101/c
Publisher Site
http://dx.doi.org/10.1101/cshperspect.a030627DOI Listing
May 2019

A Subset of TREM2 Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair Growth.

Cell Stem Cell 2019 Apr 28;24(4):654-669.e6. Epub 2019 Mar 28.

Department of Dermatology, Columbia University, New York, NY, USA; Department of Genetics & Development, Columbia University, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S19345909193001
Publisher Site
http://dx.doi.org/10.1016/j.stem.2019.01.011DOI Listing
April 2019

Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond.

Cancer J 2018 Jan/Feb;24(1):20-30

From the Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000302DOI Listing
March 2019

A role for paracrine interleukin-6 signaling in the tumor microenvironment in prostate tumor growth.

Prostate 2019 02 21;79(2):215-222. Epub 2018 Oct 21.

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23726DOI Listing
February 2019

Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.

Eur Urol Oncol 2019 Feb 26. Epub 2019 Feb 26.

Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA; Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA; Greenberg Bladder Cancer Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.01.017DOI Listing
February 2019

Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:147-164. Epub 2019 May 17.

5 Division of Hematology and Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_240837DOI Listing
January 2019

Cooperation of loss of and inflammation in prostate cancer initiation.

Dis Model Mech 2018 11 16;11(11). Epub 2018 Nov 16.

Departments of Urology, Medicine, Pathology & Cell Biology, and Systems Biology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/dmm.035139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262819PMC
November 2018

Absence of host NF-κB p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization.

Cancer Immunol Immunother 2018 Oct 21;67(10):1491-1503. Epub 2018 Jul 21.

Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University, CRB I, Rm 253, 1650 Orleans St., Baltimore, MD, 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-018-2184-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168375PMC
October 2018

The Immunobiology of Kidney Cancer.

J Clin Oncol 2018 Oct 29:JCO2018792648. Epub 2018 Oct 29.

Charles G. Drake and Mark N. Stein, Columbia University Medical Center; and Charles G. Drake, Columbia University, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.79.2648
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.79.2648DOI Listing
October 2018

Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.

Curr Oncol Rep 2018 08 18;20(9):75. Epub 2018 Aug 18.

Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, 177 Fort Washington Avenue, 6GN-435, New York, NY, 10032, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0712-z
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0712-zDOI Listing
August 2018

Combined local and systemic attacks.

Nat Biomed Eng 2018 08;2(8):564-565

Department of Medicine, Division of Hematology / Oncology, Columbia University Medical Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41551-018-0277-z
Publisher Site
http://dx.doi.org/10.1038/s41551-018-0277-zDOI Listing
August 2018

IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy.

Cell Syst 2018 07 27;7(1):92-103.e4. Epub 2018 Jun 27.

Department of Dermatology, Columbia University Medical Center, New York, NY, USA; Department of Genetics and Development, Columbia University Medical Center, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cels.2018.05.020DOI Listing
July 2018

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.

Am J Pathol 2018 06 22;188(6):1478-1485. Epub 2018 Mar 22.

Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland; Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00029440173117
Publisher Site
http://dx.doi.org/10.1016/j.ajpath.2018.02.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971230PMC
June 2018

Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model.

Prostate Cancer Prostatic Dis 2018 04 4;21(1):113-125. Epub 2017 Dec 4.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-017-0013-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897134PMC
April 2018

Inhibitors of the PD-1 Pathway in Tumor Therapy.

J Immunol 2018 01;200(2):375-383

Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115;

View Article

Download full-text PDF

Source
http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1701044
Publisher Site
http://dx.doi.org/10.4049/jimmunol.1701044DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5924692PMC
January 2018

The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas.

Eur Urol Focus 2017 12 8;3(6):584-589. Epub 2017 Feb 8.

The James Buchanan Brady Urological Institute & Department of Urology, Johns Hopkins University School of Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2017.01.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548653PMC
December 2017

Biomarkers for immunotherapy in bladder cancer: a moving target.

J Immunother Cancer 2017 11 21;5(1):94. Epub 2017 Nov 21.

New York-Presbyterian/Columbia University Medical Center, Hematology/Oncology, 177 Fort Washington Avenue, 6GN-435, New York, NY, 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0299-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697433PMC
November 2017

A phased strategy to differentiate human CD14+monocytes into classically and alternatively activated macrophages and dendritic cells.

Biotechniques 2016 1;61(1):33-41. Epub 2016 Jul 1.

The James Buchanan Brady Urological Institute at the Johns Hopkins University School of Medicine, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2144/000114435DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504907PMC
October 2017

Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Am J Surg Pathol 2017 Oct;41(10):1381-1389

Departments of *Dermatology ‡Pathology §Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center ∥The Brady Urologic Institute, Johns Hopkins University School of Medicine, Baltimore, MD Departments of †Medicine, Thoracic Oncology Service ¶Pathology #Dermatology, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000900DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657299PMC
October 2017

Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies.

J Leukoc Biol 2017 08 26;102(2):393-406. Epub 2017 May 26.

Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1189/jlb.5VMR1116-491RRDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6608078PMC
August 2017

Intravesical BCG Induces CD4 T-Cell Expansion in an Immune Competent Model of Bladder Cancer.

Cancer Immunol Res 2017 07 6;5(7):594-603. Epub 2017 Jun 6.

The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-16-0267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536898PMC
July 2017

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.

J Natl Cancer Inst 2017 04;109(4)

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and The Brady Urological Institute, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw261DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441294PMC
April 2017

LAG3 (CD223) as a cancer immunotherapy target.

Immunol Rev 2017 03;276(1):80-96

Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imr.12519DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338468PMC
March 2017

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer.

Immunotargets Ther 2017 20;6:11-16. Epub 2017 Mar 20.

The Sidney Kimmel Cancer Center; The James Buchanan Brady Urological Institute, John Hopkins Medical Institutions, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/ITT.S122497DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365325PMC
March 2017

Risk Associated With High-Dose Bicalutamide.

Authors:
Charles G Drake

J Clin Oncol 2017 02 21;35(4):471. Epub 2016 Nov 21.

Charles G. Drake, Columbia University, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.4299DOI Listing
February 2017

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

J Clin Oncol 2017 Jan 31;35(1):40-47. Epub 2016 Oct 31.

Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Eugene D. Kwon, Mayo Clinic, Rochester, MN; Charles G. Drake, Johns Hopkins University, Baltimore, MD; Karim Fizazi, University of Paris-Sud, Villejuif; Gwenaelle Gravis, Institut Paoli-Calmettes, Marseille, France; Christopher Logothetis, University of Texas MD Anderson Cancer Center, Houston, TX; Vinod Ganju, Monash University, Melbourne, Victoria; Siobhan S. Ng, St John of God Hospital, Subiaco, Western Australia; Francis X. Parnis, Adelaide Cancer Centre, Adelaide, South Australia, Australia; Jonathan Polikoff, Southern California Permanente Medical Group, San Marcos, CA; Fred Saad, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada; Piotr Humanski, Niepubliczny Zaklad Opieki Zdrowotnej Specjalista, Kutno, Poland; Josep M. Piulats, Institut Català d'Oncologia, Barcelona; Javier Puente, Hospital Clínico San Carlos, Madrid, Spain; Pablo Gonzalez Mella, Instituto Oncologico, Viña del Mar; Pablo Gonzalez Mella, Fundación Arturo Lopez Pérez, Santiago, Chile; Dirk Jaeger, University Hospital, Heidelberg, Germany; Fabio A. Franke, Hospital de Caridade de Ijuí, Ijuí, Brazil; Roman Carvajal, Hospital Regional Valentin Gomez Farias, Zapopan, Mexico; Lisa Sengeløv, Herlev Hospital, Herlev, Denmark; M. Brent McHenry, Bristol-Myers Squibb, Wallingford, CT; Arvind Varma, DOCS Inc, New York, NY; Alfonsus J. van den Eertwegh, VU University Medical Center, Amsterdam; and Winald Gerritsen, Radboud University, Nijmegen, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.1584DOI Listing
January 2017

Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.

Proc Natl Acad Sci U S A 2016 11 11;113(48):E7769-E7777. Epub 2016 Nov 11.

Department of Oncology, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1607836113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137776PMC
November 2016

Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select.

J Clin Oncol 2016 09 25;34(26):3115-6. Epub 2016 Jul 25.

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and The James Buchanan Brady Urological Institute, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.4696DOI Listing
September 2016

A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer.

J Urol 2016 Apr 18;195(4 Pt 1):880-5. Epub 2015 Nov 18.

Department of Oncology, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Department of Urology, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2015.11.024DOI Listing
April 2016

Circulating Beta-2 Microglobulin and Risk of Cancer: The Atherosclerosis Risk in Communities Study (ARIC).

Cancer Epidemiol Biomarkers Prev 2016 04 5;25(4):657-64. Epub 2016 Feb 5.

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-15-0849DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873421PMC
April 2016

Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.

Urol Oncol 2016 Apr 28;34(4):171-81. Epub 2016 Feb 28.

Department of Oncology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2016.01.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834698PMC
April 2016

Personalized Immune Therapy: A Slippery Fish?

Oncology (Williston Park) 2016 Apr;30(4):308-9

View Article

Download full-text PDF

Source
April 2016

Recent advances in immunotherapy for kidney cancer.

Discov Med 2016 04;21(116):305-13

The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
April 2016

Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.

Cancer Epidemiol Biomarkers Prev 2016 Mar 29;25(3):463-9. Epub 2015 Dec 29.

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. Department of Urology and the James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-15-0987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779655PMC
March 2016

New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.

Clin Cancer Res 2016 Feb 18;22(4):793-801. Epub 2015 Dec 18.

Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland. The Brady Urological Institute, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2015/12/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-15-1135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825862PMC
February 2016

Combination immunotherapy in renal cell carcinoma.

Authors:
Charles G Drake

Clin Adv Hematol Oncol 2016 Feb;14(2):99-100

View Article

Download full-text PDF

Source
February 2016

Prostate cancer.

Lancet 2016 Jan 11;387(10013):70-82. Epub 2015 Jun 11.

Division of Clinical Studies, The Institute of Cancer Research, London, UK; Prostate Cancer Targeted Therapy Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(14)61947-4DOI Listing
January 2016

Immune checkpoint inhibitors: a new frontier in bladder cancer.

World J Urol 2016 Jan 20;34(1):49-55. Epub 2015 Oct 20.

The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, 1800 Orleans Street, Marburg 420, Baltimore, MD, 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-015-1709-yDOI Listing
January 2016

A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells.

Cancer Immunol Res 2015 Oct 5;3(10):1175-84. Epub 2015 Jun 5.

Department of Pathology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596748PMC
October 2015

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.

Lancet Oncol 2015 Oct;16(13):e498-509

Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S147020451500007
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(15)00007-8DOI Listing
October 2015

Combined Immune Checkpoint Blockade.

Authors:
Charles G Drake

Semin Oncol 2015 Aug 3;42(4):656-62. Epub 2015 Jun 3.

Departments of Oncology and Urology, James Buchanan Brady Urological Institute; Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.05.002DOI Listing
August 2015

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

J Clin Oncol 2015 Jun 30;33(18):2013-20. Epub 2015 Mar 30.

David F. McDermott, Beth Israel Deaconess Medical Center; Toni K. Choueiri, Dana-Farber Cancer Institute/Brigham and Women's Hospital; Igor Puzanov and F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Charles G. Drake, Julie R. Brahmer, Hans J. Hammers, Suzanne L. Topalian, and Drew M. Pardoll, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Richard D. Carvajal, Memorial Sloan-Kettering Cancer Center, New York, NY; Jon M. Wigginton, Georgia D. Kollia, Ashok Gupta, Dan McDonald, and Vindira Sankar, Bristol-Myers Squibb, Princeton, NJ; Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Nashville, TN; and Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.1041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517051PMC
June 2015

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.

Cancer Immunol Res 2015 Apr 19;3(4):345-55. Epub 2014 Dec 19.

Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390444PMC
April 2015

Immune checkpoint blockade: a common denominator approach to cancer therapy.

Cancer Cell 2015 Apr 6;27(4):450-61. Epub 2015 Apr 6.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108150008
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2015.03.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400238PMC
April 2015

Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.

BioDrugs 2014 Dec;28(6):513-26

Department of Internal Medicine, University of Massachusetts Medical School, Worcester, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40259-014-0111-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888066PMC
December 2014

PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.

Cancer Immunol Res 2014 Dec;2(12):1132-41

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0193DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695990PMC
December 2014

A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II.

Cancer Epidemiol Biomarkers Prev 2014 Nov 22;23(11):2561-7. Epub 2014 Aug 22.

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Department of Urology and James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-14-0010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648294PMC
November 2014

Cancer immunotherapy highlights from the 2014 ASCO Meeting.

Cancer Immunol Res 2014 Aug;2(8):714-9

Icahn School of Medicine at Mount Sinai, New York, New York

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0119DOI Listing
August 2014